Efficacy of capecitabine versus 5-fluorouracil in colorectal and gastric cancers: a meta-analysis of individual data from 6171 patients
Open accessThe DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
Abstract
Background To compare the effects of oral capecitabine-containing chemotherapy regimens with i.v. 5-fluorouracil (5-FU)-containing chemotherapy regimens on overall survival in patients with gastrointestinal cancers.Methods A meta-analysis, based on individual patient data from six randomised non-inferiority trials, was carried out at the request of regulatory authorities to compare the effects of single-agent capecitabine or capecitabine-containing chemotherapy versus matched 5-FU-based regimens in terms of overall survival in patients with stage III colon, metastatic colorectal or advanced gastric cancer.Results Data from a total of 6171 patients with stage III colon cancer (n = 1987), metastatic colorectal cancer (n = 3868) or advanced gastric cancer (n = 316) were included. A total of 3097 patients were treated with capecitabine-containing chemotherapy and 3074 patients with 5-FU-containing chemotherapy. The unadjusted hazard ratio for overall survival for capecitabine-containing chemotherapy versus 5-FU-containing chemotherapy was 0.94 (95% confidence interval 0.89-1.00; P = 0.0489).Conclusions Oral capecitabine is at least equivalent to i.v. 5-FU in terms of overall survival in patients with gastrointestinal cancers. Capecitabine and 5-FU can be used interchangeably in these patient populations.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Capecitabine, an oral FP that is enzymatically converted to 5-FU, was shown to be equivalent to 5-FU in survival benefit [138].”
From Recent Advances in Therapeutic Strategies to Improve Colorectal Cancer Treatment (2024) · cites this paper as [138]
Citations
Cites
Saltz, L. B., Clarke, S., Díaz-Rubio, E., Scheithauer, W., Figer, A., Wong, R., Koski, S., Lichinitser, M., Yang, T.-S., Rivera, F., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.9930 · Cited by 2,955
Self-citationCapecitabine and Oxaliplatin for Advanced Esophagogastric Cancer
Cunningham, D., Starling, N., Rao, S., Iveson, T., Nicolson, M., Coxon, F., Middleton, G., Daniel, F., Oates, J., & Norman, A. R. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa073149 · Cited by 2,285
Self-citationCapecitabine as Adjuvant Treatment for Stage III Colon Cancer
Twelves, C., Wong, A., Nowacki, M. P., Abt, M., Burris, H., Carrato, A., Cassidy, J., Cervantes, A., Fagerberg, J., Georgoulias, V., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043116 · Cited by 1,248
Self-citationHoff, P. M., Ansari, R., Batist, G., Cox, J., Kocha, W., Kuperminc, M., Maroun, J., Walde, D., Weaver, C., Harrison, E., et al. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.8.2282 · Cited by 1,130
Self-citationVan Cutsem, E., Twelves, C., Cassidy, J., Allman, D., Bajetta, E., Boyer, M., Bugat, R., Findlay, M., Frings, S., Jahn, M., et al. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.21.4097 · Cited by 1,032
Self-citationCassidy, J., Clarke, S., Díaz-Rubio, E., Scheithauer, W., Figer, A., Wong, R., Koski, S., Lichinitser, M., Yang, T.-S., Rivera, F., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.9898 · Cited by 862
Self-citationKang, Y.-K., Kang, W.-K., Shin, D.-B., Chen, J., Xiong, J., Wang, J., Lichinitser, M., Guan, Z., Khasanov, R., Zheng, L., et al. (2009) · Annals of Oncology · doi:10.1093/annonc/mdn717 · Cited by 764
Self-citationOkines, A. F. C., Norman, A. R., McCloud, P., Kang, Y.-K., & Cunningham, D. (2009) · Annals of Oncology · doi:10.1093/annonc/mdp047 · Cited by 258
Self-citationSargent, D. J., Patiyil, S., Yothers, G., Haller, D. G., Gray, R., Benedetti, J., Buyse, M., Labianca, R., Seitz, J. F., O'Callaghan, C. J., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.10.4323 · Cited by 240
Tang, P. A., Bentzen, S. M., Chen, E. X., & Siu, L. L. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.08.1935 · Cited by 236
Cited by
Pharmacologic resistance in colorectal cancer: a review
Hammond, W. A., Swaika, A., & Mody, K. (2016) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758834015614530 · Cited by 519
Nie, K., Shi, L., Chen, Q., Hu, X., Jabbour, S. K., Yue, N., Niu, T., & Sun, X. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-2997 · Cited by 414
Standing the test of time: targeting thymidylate biosynthesis in cancer therapy
Wilson, P. M., Danenberg, P. V., Johnston, P. G., Lenz, H.-J., & Ladner, R. D. (2014) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2014.51 · Cited by 388
Gao, Y., Xiao, X., Zhang, C., Yu, W., Guo, W., Zhang, Z., Li, Z., Feng, X., Hao, J., Zhang, K., et al. (2017) · Journal of Pineal Research · doi:10.1111/jpi.12380 · Cited by 189
Lee, A. W. M., Ngan, R. K. C., Tung, S. Y., Cheng, A. C. K., Kwong, D. L. �., Lu, T., Chan, A. T. �., Chan, L. L. K., Yiu, H. H. Y., Ng, W. T., et al. (2014) · Cancer · doi:10.1002/cncr.29208 · Cited by 178
Metadata
- Authors
- Cassidy, J., Saltz, L., Twelves, C., Van Cutsem, E., Hoff, P., Kang, Y., Saini, J. P., Gilberg, F., & Cunningham, D.
- Affiliations
- University of Glasgow (GB)
- Memorial Sloan Kettering Cancer Center (US)
- University of Leeds (GB)
- Hospital Sírio-Libanês (BR)
- Asan Medical Center (KR)
- F. Hoffmann-La Roche AG (CH)
- Royal Marsden Hospital (GB)
- Corresponding author
- Cassidy, J.
- Venue
- Annals of Oncology
- Publisher
- Elsevier BV
- Published
- 2011-12
- Volume
- 22
- Issue
- 12
- Pages
- 2604-2609
- ISSN
- 0923-7534 (ISSN-L)
- OpenAlex
- W2146874279
- Cited by
- 90
- References
- 17
- Citations by year
- 2026: 3 · 2025: 1 · 2024: 7 · 2023: 3 · 2022: 4 · 2021: 7 · 2020: 3 · 2019: 3 · 2018: 8 · 2017: 11 · 2016: 6 · 2015: 6 · 2014: 9 · 2013: 8 · 2012: 8
- FWCI
- 0.79
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/open-access/userlicense/1.0/ (vor, 2913 d)
- Locations
- Annals of Oncology (publishedVersion)
- PubMed (publishedVersion)
- ENLIGHTEN (Jurnal Bimbingan dan Konseling Islam) (submittedVersion)
- HighWire Press Open Archive (submittedVersion)
- Funders
- Roche
- Topics
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Health Sciences › Medicine › Oncology › Gastric Cancer Management and Outcomes
- Health Sciences › Medicine › Oncology › Colorectal Cancer Surgical Treatments
- Keywords
- capecitabine, 5-fluorouracil, colorectal cancer, gastric cancer, metastatic colorectal cancer, stage III colon cancer, advanced gastric cancer, oral chemotherapy, overall survival, non-inferiority, individual patient data
- MeSH terms
- Capecitabine, Antineoplastic Agents, Deoxycytidine, Female, Fluorouracil, Humans, Male, Stomach Neoplasms, Colorectal Neoplasms, Multivariate Analysis, Randomized Controlled Trials as Topic, Treatment Outcome, Kaplan-Meier Estimate
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Efficacy of capecitabine versus 5-fluorouracil in colorectal and gastric cancers: a meta-analysis of individual data from 6171 patients. https://app.cochat.ai/papers/10.1093/annonc/mdr031
- The paper
- Cassidy, J., Saltz, L., Twelves, C., Van Cutsem, E., Hoff, P., Kang, Y., Saini, J. P., Gilberg, F., & Cunningham, D. (2011). Efficacy of capecitabine versus 5-fluorouracil in colorectal and gastric cancers: a meta-analysis of individual data from 6171 patients. Annals of Oncology. https://doi.org/10.1093/annonc/mdr031
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.